Millions of people are touched by diseases related to angiogenesis and hyperpermeability.  Research has implicated MetAP2 in each of these, including:

    Cancer

    Lung diseases

          idiopathic pulmonary fibrosis

          cystic fibrosis

           interstitial lung disease

    Endometriosis

    Eye diseases

            age-related Macular Degeneration (AMD)

            diabetic retinopathy

    Rheumatoid arthritis

    IL2 induced edema.

SynDevRx has assembled an all-star team of clinical oncologists, researchers, professors and drug development experts in an effort to help in the fight against these diseases, and to improve the lives of people living with them. Our mission is to clinically validate promising therapeutics that target MetAP2 by advancing them through Phase II clinical trials. At that point, we intend on partnering with larger biotech/pharmaceutical companies for completion of Phase III pivotal trials and FDA drug registration and approval.

Our lead compound — Caplostatin™ — has an impressive pedigree; coming from the laboratory of Dr. Judah Folkman, Children's Hospital, Harvard Medical School in Boston. Dr. Folkman is widely considered the father of anti-angiogenesis — the process by which tumors draw in new blood vessels in order to maintain their rate of growth. His research in this field is strongly supported by work from the labs of Bruce Zetter, PhD, Dr. Daniel Von Hoff, Dr. Roy Herbst, PhD, and Rakesh Jain, PhD., all recognized leaders in this area of research and treatment, and all advisors to SynDevRx.

Patient enrollment in our Phase I clinical trials is expected in 2009. Information on current clinical clinical trials can be found here.